Table 1.
Select baseline characteristics in the intention-to-treat population
| Characteristics | Avelumab | Chemotherapy |
|---|---|---|
| (n = 185) | (n = 186) | |
| Age, median (range), years | 59 (29–86) | 61 (18–82) |
| Sex | ||
| Male | 140 (75.7) | 127 (68.3) |
| Female | 45 (24.3) | 59 (31.7) |
| ECOG PS | ||
| 0 | 66 (35.7) | 62 (33.3) |
| 1 | 119 (64.3) | 124 (66.7) |
| Histology | ||
| Tubular | 67 (36.2) | 66 (35.5) |
| Signet ring | 42 (22.7) | 36 (19.4) |
| Mucinous | 15 (8.1) | 21 (11.3) |
| Papillary | 3 (1.6) | 5 (2.7) |
| Other | 57 (31.3) | 58 (31.2) |
| Missing | 1 (0.5) | 0 |
| Tumour site | ||
| Gastric | 122 (65.9) | 138 (74.2) |
| Gastro-oesophageal junction | 63 (34.1) | 48 (25.8) |
| Geographic region | ||
| Europe | 111 (60.0) | 114 (61.3) |
| Asia | 46 (24.9) | 47 (25.3) |
| North America | 14 (7.6) | 11 (5.9) |
| Rest of the world | 14 (7.6) | 14 (7.5) |
| Race | ||
| White | 119 (64.3) | 117 (62.9) |
| Asian | 47 (25.4) | 47 (25.3) |
| Black | 1 (0.5) | 1 (0.5) |
| Not collected/missing | 18 (9.7) | 21 (11.4) |
| Time since diagnosis of metastatic disease, median (range), months | 13.6 (2–106) | 13.9 (3–64) |
| Number of prior anticancer therapies for locally advanced/metastatic disease | ||
| 1a | 26 (14.1) | 22 (11.8) |
| 2 | 158 (85.4) | 161 (86.6) |
| 3 | 0 | 1 (0.5) |
| ≥4 | 0 | 0 |
| Missing | 0 | 2 (1.1) |
| PD-L1 status, ≥1% staining threshold on tumour cells | ||
| Positive | 46 (29.3) | 39 (24.4) |
| Negative | 111 (70.7) | 121 (75.6) |
Data are number of patients (%) unless specified otherwise.
a
Patients who progressed on neoadjuvant therapy without receiving surgery or adjuvant therapy within 6 months of treatment discontinuation were considered to have received one line of prior treatment of advanced, inoperable disease.
ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death ligand-1.